TABLE 1.
Geographic differences in the frequency of isolation and in vitro susceptibility of Candida krusei to voriconazolea
| Region and country | Total no. of Candida isolates | Total no. (%) of C. krusei isolates | % of C. krusei isolates in the following category:
|
||
|---|---|---|---|---|---|
| S | SDD | R | |||
| Asia-Pacific | 26,580 | 350 (1.2) | 83.7 | 10.0 | 6.3 |
| Australia | 731 | 27 (3.7) | 100.0 | ||
| China | 7,663 | 142 (1.9) | 83.8 | 7.0 | 9.2 |
| India | 356 | 8 (2.2) | 87.5 | 12.5 | |
| Indonesia | 10 | 0 (0.0) | |||
| Malaysia | 10,510 | 142 (1.3) | 78.9 | 16.2 | 4.9 |
| South Korea | 3,515 | 10 (0.3) | 80.0 | 10.0 | 10.0 |
| Taiwan | 3,083 | 19 (0.6) | 94.7 | 5.3 | |
| Thailand | 632 | 2 (0.03) | 100.0 | ||
| Europe | 75,594 | 2.459 (3.3) | 82.1 | 10.1 | 7.8 |
| Belgium | 5,213 | 182 (3.5) | 97.3 | 1.6 | 1.1 |
| Czech Republic | 6,541 | 498 (7.6) | 74.9 | 15.1 | 10.0 |
| France | 2,363 | 57 (2.4) | 78.9 | 12.3 | 8.8 |
| Germany | 2,489 | 110 (4.4) | 90.9 | 4.5 | 4.5 |
| Greece | 589 | 15 (2.5) | 80.0 | 20.0 | |
| Hungary | 12,655 | 519 (4.1) | 70.9 | 17.9 | 11.2 |
| Italy | 5,172 | 177 (3.4) | 89.8 | 5.1 | 5.1 |
| The Netherlands | 6,422 | 31 (0.5) | 93.5 | 3.2 | 3.2 |
| Norway | 253 | 6 (2.4) | 66.7 | 33.2 | |
| Poland | 1,022 | 61 (6.0) | 98.4 | 1.6 | |
| Portugal | 2,843 | 51 (1.8) | 96.1 | 3.9 | |
| Russia | 5,965 | 203 (3.4) | 86.7 | 7.4 | 5.9 |
| Slovakia | 3,559 | 182 (5.1) | 90.1 | 5.5 | 4.4 |
| Spain | 6,328 | 126 (2.0) | 77.0 | 8.7 | 14.3 |
| Switzerland | 1,706 | 47 (2.8) | 93.6 | 4.3 | 2.1 |
| Turkey | 1,320 | 28 (2.1) | 89.3 | 3.6 | 7.1 |
| United Kingdom | 11,154 | 166 (1.5) | 81.9 | 7.8 | 10.2 |
| Latin America | 19,079 | 206 (1.1) | 74.8 | 9.2 | 16.0 |
| Argentina | 6,347 | 61 (1.0) | 93.8 | 4.7 | 1.6 |
| Brazil | 3,764 | 41 (1.1) | 65.9 | 34.1 | |
| Colombia | 3,679 | 55 (1.5) | 61.8 | 20.0 | 18.2 |
| Ecuador | 2,607 | 13 (0.5) | 76.9 | 15.4 | 7.7 |
| Mexico | 889 | 11 (1.2) | 63.6 | 36.4 | |
| Venezuela | 1,793 | 22 (1.2) | 72.7 | 13.6 | 13.6 |
| Africa/Middle East | 6,452 | 108 (1.7) | 88.0 | 6.5 | 5.5 |
| South Africa | 5,286 | 84 (1.6) | 86.9 | 7.1 | 6.0 |
| Israel | 814 | 19 (2.3) | 94.7 | 5.3 | |
| Saudi Arabia | 352 | 5 (1.4) | 80.0 | 20.0 | |
| North America | 9,782 | 325 (3.3) | 92.3 | 3.4 | 4.3 |
| Canada | 913 | 16 (1.8) | 93.8 | 6.3 | |
| United States | 8,869 | 309 (3.5) | 92.2 | 3.2 | 4.5 |
| Total | 137,487 | 3,448 (2.5) | 82.9 | 9.3 | 7.8 |
a
Isolates were obtained from 124 institutions. Voriconazole disk testing was performed in accordance with CLSI document M44-A (25). The interpretive breakpoints (zone diameters) were as follows: susceptible (S), ≥17 mm; susceptible dose dependent (SDD), 14 to 16 mm; resistant (R), ≤13 mm.